I-Tagrisso: ukwelapha umdlavuza wamaphaphu

-Delile

• Intengo
• Yenzelwe ini
• Isetshenziswa kanjani
• Imiphumela emibi engaba khona
• Ngubani ongafanele asebenzise

I-Tagrisso ngumuthi olwa nomdlavuza osetshenziselwa ukwelapha umdlavuza wamaphaphu weseli ongeyona omncane.

Leli khambi liqukethe i-Osimertinib, into evimba ukusebenza kwe-EGFR, i-receptor cell yomdlavuza elawula ukukhula kwayo nokuphindaphindeka. Ngakho-ke, amangqamuzana e-tumor ahluleka ukukhula kahle futhi ijubane lokukhula komdlavuza linciphisa ijubane, lithuthukise imiphumela yezinye izindlela zokwelapha, njenge-chemotherapy.

I-Tagrisso ikhiqizwa ngamalabhorethri e-AstraZeneca futhi angathengwa emakhemisi anencwadi kadokotela, ngamaphilisi angama-40 noma angama-80 mg.

Intengo

Yize lo muthi usuvele uvunyelwe yi-Anvisa eBrazil, awukathengiswa.

Yenzelwe ini

I-Tagrisso ikhonjisiwe ekwelashweni kwabantu abadala abanomdlavuza wamaphaphu wesifo samangqamuzana ongekho omncane noma ama-metastases ngokuguqulwa okuhle kwe-T790M kuhlobo lwe-EGFR receptor.

Isetshenziswa kanjani

Ukwelashwa ngalo muthi kufanele kuqondiswe njalo yi-oncologist, ngokwezinga lokukhula komdlavuza.

Kodwa-ke, umthamo onconyiwe yi-1 80 mg tablet noma 2 tablet 40 mg kanye ngosuku.

Imiphumela emibi engaba khona

Ukusetshenziswa kweTagrisso kungadala imiphumela emibi efana nohudo, ubuhlungu besisu, isifuba kanye nesikhumba esilumayo nezinguquko ekuhlolweni kwegazi, ikakhulukazi kwinani lama-platelets, ama-leukocyte nama-neutrophils.

Ngubani ongafanele asebenzise

I-Tagrisso akufanele isetshenziswe ngabesifazane abakhulelwe noma abancelisayo, kanye nabantu abaphikisana nanoma yiziphi izingxenye zefomula. Ngaphezu kwalokho, akufanele uthathe i-wort yaseSt.John ngesikhathi sokwelashwa ngaleli thuluzi.